Faculty profile

Li Zhang

ResearcherLaboratory Medicine & PathobiologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Li Zhang

Researcher

Laboratory Medicine & Pathobiology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
15 publications in the last five years, latest in 2026.
Senior (last) author on 8 recent papers, a sign of leading a research group.
Principal investigator on 4 research grants (4 CIHR), most recently in 2019.
Supervised 1 trainee who won CIHR awards, most recently in 2009.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Immunotherapy Acute Lymphoblastic Leukemia (All)Acute Myeloid Leukemia (Aml)Adoptive Cellular Therapy (Act)Cancer Chimeric Antigen Receptors (Car)Double-Negative T Cells (Dnts)Non-Small Cell Lung Cancer (Nsclc)

Latest papers

Validation of Dried Blood Spot Immunoreactive Trypsinogen as a Biomarker of Exocrine Pancreas Function in Children With Pancreas Disease.
The American journal of gastroenterology · 2026
Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.
Leukemia · 2026
Mitochondrial RNA degradation regulates differentiation, stemness, and immune sensitivity in acute myeloid leukemia.
Nature communications · 2026

All 80 publications

Latest funding

Developing a platform for "off-the-shelf" CAR-T cell therapies for cancer using double negative T cells
CIHR · 2019 · Nominated PI
$703,800
Porphyrin Nanomedicine for Cancer Imaging and Therapy
CIHR · 2016 · Co-investigator
$3,300,088
A new cellular immunotherapy to treat acute myeloid leukemia
CIHR · 2015 · Nominated PI
$183,670

All 9 grants and awards

80 publications.

Validation of Dried Blood Spot Immunoreactive Trypsinogen as a Biomarker of Exocrine Pancreas Function in Children With Pancreas Disease.

Gummadi VV, Ren A, Zhang L, Eagle S, Jung B, Arenos-Abril J, Chavhan GB, Adeli K, Henderson M, Sepiashvili L, Gonska T

The American journal of gastroenterology2026

DOI: 10.14309/ajg.0000000000003792 PMID: 41090999

Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.

Duong N, Khan DH, Thomas GE, Feng Y, Hurren R, Lee JB, St-Germain J, Drimmer L, Yan Y, Zhang LX, Fang KK, Ling D, Ma ML, MacLean N, Gronda M, Rondeau V, Brown BD, Matellán L, Jones CL, Chang H, Arruda A, Xie S, Pelletier L, Minden MD, Zhang L, Kornblau SM, Raught B, Jacobs K, Jacobs MG, Goede D, Spadavecchio V, Schimmer AD

Leukemia2026

DOI: 10.1038/s41375-026-02949-8 PMID: 41998300

Mitochondrial RNA degradation regulates differentiation, stemness, and immune sensitivity in acute myeloid leukemia.

Thomas GE, Voisin V, Nouri K, Hurren R, Fang KK, Chegini A, Gronda M, Yan Y, MacLean N, Jitkova Y, Ling D, Ma M, Wang XM, Arruda A, Spadavecchio V, Minden MD, Zhang L, Lee JB, Schimmer AD

Nature communications2026

DOI: 10.1038/s41467-026-73558-3 PMID: 42218125

Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy.

Tin E, Khatri I, Fang K, Na Y, Nawata M, Arteaga J, Minden MD, Rutella S, Lee J, Zhang L

Journal for immunotherapy of cancer2025Senior author

DOI: 10.1136/jitc-2024-010684 PMID: 40246580

Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD.

Lee J, Kang H, Chen B, Na Y, Khatri I, Soares F, He HH, Law AD, Pan T, Gerbitz A, Zhu X, Minden MD, Zhang L

Journal of experimental & clinical cancer research : CR2025Senior author

DOI: 10.1186/s13046-024-03247-w PMID: 39876025

Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses.

Reid KT, Colpitts SJ, Mathews JA, Santos Carreira A, Murphy JM, Borovsky DT, Jegatheeswaran S, Cui W, Alfaro Moya T, Sachewsky N, An J, Xia Y, Mortha A, Lee JB, Zhang L, Novitzky-Basso I, Mattsson J, Crome SQ

Cell reports2025

DOI: 10.1016/j.celrep.2024.115102 PMID: 39721022

Allogeneic double-negative T-cell therapy for acute myeloid leukemia.

Tin E, Lee J, Zhang L

Current opinion in pharmacology2025Senior author

DOI: 10.1016/j.coph.2025.102537 PMID: 40441065

SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity.

Tin E, Rutella S, Khatri I, Na Y, Yan Y, MacLean N, Vadakekolathu J, Minden MD, Schimmer AD, Lee J, Zhang L

Blood cancer discovery2025Senior author

DOI: 10.1158/2643-3230.bcd-24-0140 PMID: 39928733

Double-negative T cells utilize a TNFα-JAK1-ICAM-1 cytotoxic axis against acute myeloid leukemia.

Tin E, Lee JB, Khatri I, Na Y, Minden MD, Zhang L

Blood advances2024Senior author

DOI: 10.1182/bloodadvances.2023011739 PMID: 38547431

Author Correction: In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.

Dervovic D, Malik AA, Chen ELY, Narimatsu M, Adler N, Afiuni-Zadeh S, Krenbek D, Martinez S, Tsai R, Boucher J, Berman JM, Teng K, Ayyaz A, Lü Y, Mbamalu G, Loganathan SK, Lee J, Zhang L, Guidos C, Wrana J, Valipour A, Roux PP, Reimand J, Jackson HW, Schramek D

Nature communications2023

DOI: 10.1038/s41467-023-41255-0 PMID: 37670013

Developing a platform for "off-the-shelf" CAR-T cell therapies for cancer using double negative T cells

Nominated PICIHR2019Project Grant

Principal investigators: Zhang, Li

Keywords: Acute Lymphoblastic Leukemia (All); Acute Myeloid Leukemia (Aml); Adoptive Cellular Therapy (Act); Cancer; Chimeric Antigen Receptors (Car); Double-Negative T Cells (Dnts); Immunotherapy; Non-Small Cell Lung Cancer (Nsclc)

$703,800

Porphyrin Nanomedicine for Cancer Imaging and Therapy

Co-investigatorCIHR2016Foundation Grant

Principal investigators: Zheng, Gang

Keywords: Blood Brain Barrier; Cancer Imaging; Image-Guided Therapy; Immunotherapy; Lipoprotein; Microbubbles; Nanoparticle; Photodynamic Therapy; Photothermal Therapy; Radiotherapy

$3,300,088

A new cellular immunotherapy to treat acute myeloid leukemia

Nominated PICIHR2015Proof of Principle Program - Phase II

Principal investigators: Zhang, Li

Keywords: Acute Myeloid Leukemia; Auto Immunity; Cancer Immunology; Chemotherapy; Double Negative T Cells; Graft-Vs-Host Disease; Immunotherapy; Leukemia; Stem Cell Transplantation; Xenograft Models

$183,670

Establishing donor-specific transplantation tolerance by harnessing DN regulatory T cells

Nominated PICIHR2015Operating Grant

Principal investigators: Zhang, Li

Keywords: Animal Models; B Cells; Double Negative Treg; Flow Cytometry; Humanized Mice; Immunosuppression; Mouse Heart Transplantation; Regulatory Cells; Tolerance; Transplantation

$676,395

Development of personalized immunotherapy to treat lung cancer using gamma-delta-T cells

Nominated PICIHR2011Operating Grant

Principal investigators: Zhang, Li

Keywords: Adoptive Cellular Therapy; Ex Vivo T Cell Expansion; Gamma-Delta T-Cells; Human; Lung Cancer; Trail

$785,005

The contribution of fibrinogen-like protein 2 in double negative T cell mediated immunosuppression.

SupervisorCIHR2009Master's Award: Frederick Banting and Charles Best Canada Graduate Scholarships

Principal investigators: Wong, Aaron

Keywords: Autoimmunity; Double Negative Regulatory T Cells; Fgl2; Fibroleukin; Immune Regulation; Regenerative Medicine; Supressor; Tolerance; Transplantation

$17,500

CIHR Training Program in Regenerative Medicine

Co-investigatorCIHR2008Training Grant

Principal investigators: Levy, Gary A

Keywords: Gene Therapy; Regenerative Medicine; Stem Cells; Tolerance; Transplantation

$1,950,000

The Terry Fox Foundation Strategic Health Research Training Program in Molecular Pathology of Cancer at CIHR

Co-investigatorCIHR2008Terry Fox Foundation Training Grant in Cancer Research at CIHR -Full application

Principal investigators: Tsao, Ming-Sound

Keywords: Clinician-Scientists; Molecular Pathology; Oncology; Pathology; Translational Research

The Canadian Regenerative Medicine Network (CRM-Net) / Le Réseau Canadien de Médecine Régénérative

Co-investigatorNSERC2003Networks of Centres of Excellence

Principal investigators: Sefton, Michael

$25,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Li Zhang

Research

Latest papers

Latest funding

Validation of Dried Blood Spot Immunoreactive Trypsinogen as a Biomarker of Exocrine Pancreas Function in Children With Pancreas Disease.

Intracellular IL-23R is necessary for mitotic spindle formation and viability in AML.

Mitochondrial RNA degradation regulates differentiation, stemness, and immune sensitivity in acute myeloid leukemia.

Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy.

Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD.

Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T&#xa0;cell responses.

Allogeneic double-negative T-cell therapy for acute myeloid leukemia.

SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity.

Double-negative T cells utilize a TNF&#x3b1;-JAK1-ICAM-1 cytotoxic axis against acute myeloid leukemia.

Author Correction: In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.

The Canadian Regenerative Medicine Network (CRM-Net) / Le Réseau Canadien de Médecine Régénérative

Frequent collaborators

Ming-Sound Tsao

Mihaela Pop

Cynthia Guidos

Agata Bartczak

Daniel Schramek

Jeffrey Wrana

Mark Cattral

Zhengping Jia

Jonas Mattsson

Tanja Gonska

Stephanie Xie

Tommy Alfaro Moya

Khosrow Adeli

Paul Dorian

Arthur Mortha

Fang Liu

Denise Guerriere

Mingyao Liu

Andrew Ramadeen

Myron Cybulsky

Brian Raught

Ren-Ke Li

Jennifer Gommerman

Laurence Pelletier

Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses.

Double-negative T cells utilize a TNFα-JAK1-ICAM-1 cytotoxic axis against acute myeloid leukemia.